GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agios Pharmaceuticals Inc (LTS:0HB0) » Definitions » Short-Term Debt

Agios Pharmaceuticals (LTS:0HB0) Short-Term Debt : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Agios Pharmaceuticals Short-Term Debt?

Agios Pharmaceuticals's Short-Term Debt for the quarter that ended in Mar. 2024 was $0.00 Mil.


Agios Pharmaceuticals Short-Term Debt Historical Data

The historical data trend for Agios Pharmaceuticals's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agios Pharmaceuticals Short-Term Debt Chart

Agios Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Agios Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Agios Pharmaceuticals Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Agios Pharmaceuticals Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Agios Pharmaceuticals's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Agios Pharmaceuticals (LTS:0HB0) Business Description

Traded in Other Exchanges
Address
88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

Agios Pharmaceuticals (LTS:0HB0) Headlines

No Headlines